Identification of otud7b inhibitor 7bi and its application in reducing growth of nsclc and leukemia cells
AssigneesThe University of North Carolina at Chapel Hill, Atomwise Inc.
InventorsPengda Liu, Jianfeng Chen, Nicholas Brown, Christian Laggner
Life of this patent
Estimating the term…
Abstract
Provided is a composition for targeting OTUD7B. The composition includes a component sufficient to block or reduce OTUD7B-mediated deubiquitination of GβL in a cell. The component can include 7Bi and variants thereof. Also provided are methods of treating cancer and related conditions, including administering to a cancer patient a OTUD7B catalytic inhibitor, including a 7Bi or variant thereof.
Claims22
A composition for targeting OTUD7B, the composition comprising a component sufficient to block and/or reduce OTUD7B-mediated deubiquitination of GβL in a cell, wherein the component comprises 7Bi and variants thereof.
(canceled)
An OTUD7B catalytic inhibitor, the catalytic inhibitor comprising a 7Bi compound or variant thereof.
A method of treating cancer and related conditions, the method comprising administering to a subject having cancer or suspected of suffering from cancer a composition comprising a OTUD7B catalytic inhibitor, wherein the OTUD7B catalytic inhibitor comprises a 7Bi or variant thereof.
(canceled)
Dependencies are inferred from the claim text.